ESMO 2025丨An Academic Feast Awaits — Highlights from the Uro-Oncology Field You Won’t Want to Miss!

ESMO 2025丨An Academic Feast Awaits — Highlights from the Uro-Oncology Field You Won’t Want to Miss!

At the highly anticipated ESMO Congress, a wealth of cutting-edge advances will be presented, with uro-oncology standing out as one of the most vibrant and fast-evolving fields. This year, 22 Late-Breaking Abstracts (LBAs) will be showcased, accounting for nearly half of all oral presentations (45 in total) within the uro-oncology track — a testament to the field’s dynamic research momentum and strong clinical relevance.Oncology Frontier – Urology Frontier has carefully selected ten key studies and invited leading Chinese experts to share their insights and expectations.
Professor Xu Danfeng: Moving Beyond the “One-Size-Fits-All” Approach — Achieving Maximal Nephron Preservation for Hilar Renal Tumors Through TAPD Technology and Personalized Suturing — The Chinese Solution | 2025 Pujiang Uro-Oncology Academic Conference 

Professor Xu Danfeng: Moving Beyond the “One-Size-Fits-All” Approach — Achieving Maximal Nephron Preservation for Hilar Renal Tumors Through TAPD Technology and Personalized Suturing — The Chinese Solution | 2025 Pujiang Uro-Oncology Academic Conference 

Editor’s Note:In recent years, new diagnostic and therapeutic innovations in renal cancer have continued to emerge, providing clinicians with a growing range of treatment options. The widespread adoption of robot-assisted partial nephrectomy (RAPN) has enabled patients to achieve both oncological control and functional preservation. During the 2025 Pujiang Uro-Oncology Academic Conference, leading domestic and international experts in uro-oncology gathered to explore cutting-edge advances and surgical innovations in renal cancer. In this interview, Professor Xu Danfeng from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shares insights from his team’s pioneering surgical concepts and techniques for managing complex hilar renal tumors, offering valuable perspectives for peers in the field.
Professor Wei Qiang: Advancing Innovation Across the Entire Continuum of Uro-Oncology Care and Making Robots Trusted Surgical Partners | 2025 Pujiang Uro-Oncology Academic Conference 

Professor Wei Qiang: Advancing Innovation Across the Entire Continuum of Uro-Oncology Care and Making Robots Trusted Surgical Partners | 2025 Pujiang Uro-Oncology Academic Conference 

The 2025 Pujiang Uro-Oncology Academic Conference was successfully held in Shanghai on August 22–23, 2025. Centered on the theme “Precision Breakthroughs · Integrated Innovation · Optimized Continuum of Care,” the conference brought together numerous domestic and international experts to explore innovation in uro-oncology diagnosis and treatment, multidisciplinary collaboration (MDT), and translational research. Oncology Frontier – Urology Frontier interviewed Professor Wei Qiang of West China Hospital, Sichuan University, a member of the conference presidium, to discuss the highlights and driving impact of the event, as well as new advances in robotic surgery for urological tumors.
ISEH 2025 | Professor Xue Feng: AAV Vector Gene Therapy Driving Innovation in Hemophilia B Treatment in China

ISEH 2025 | Professor Xue Feng: AAV Vector Gene Therapy Driving Innovation in Hemophilia B Treatment in China

The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held in Kumamoto, Japan, from September 24 to 27. The event brought together leading global experts to discuss cutting-edge advances in basic hematology, immunology, stem cell biology, and cellular and gene therapies. One of the highlights of the meeting was the China–Japan Joint Symposium on Stem Cell and Cell Therapy, which drew significant attention. Professor Xue Feng from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), delivered an insightful presentation titled “Adeno-Associated Virus Vector Expressing Factor IX Padua in Treating Hemophilia B in China.” Following the presentation, Oncology Frontier – Hematology Frontier conducted an exclusive interview with Professor Xue to explore this innovative approach and its future clinical prospects.